Brief: Amplia Therapeutics Announces Placement And Fully Underwritten 1 For 4 Entitlement Offer
Nov 8 (Reuters) - Amplia Therapeutics Ltd ATX.AX :
* PLACEMENT AND FULLY UNDERWRITTEN 1 FOR 4 ENTITLEMENT OFFER
TO
RAISE A$12.4 MILLION
* POISED TO INITIATE A PHASE 2 CLINICAL TRIAL OF ITS FAK
INHIBITOR
AMP945 IN PATIENTS WITH PANCREATIC CANCER
* PLACEMENT AT OFFER PRICE OF A$0.18 PER NEW SHARE
Source text for Eikon: ID:nASX5nBnkj
Further company coverage: ATX.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amplia Therapeutics
See all newsBrief: Amplia Therapeutics Signs Collaboration And Supply Agreement With Lilly
Australia's Amplia rises to 4-month high on Eli Lilly cancer drug trial collaboration
Brief: Amplia Therapeutics Says Warwick Tong Will Retire As Board Chairman
Brief: Amplia Therapeutics Reports Four Additional Complete Responses And Improved Overall Survival Data In Accent Pancreatic Cancer Trial
Brief: Amplia Therapeutics Requests Trading Halt Pending Clinical Trial Results Announcement